

# Past and present treatment of pancreatic adenocarcinoma treatment modality

Seminars in Oncology

29, 2-8

DOI: [10.1053/sonc.2002.37382](https://doi.org/10.1053/sonc.2002.37382)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Role of Environmental Carcinogens, Viruses, and Genetic. <i>Cancer Biology and Therapy</i> , 2002, 1, 347-352.	1.5	280
2	Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. <i>Anti-Cancer Drugs</i> , 2002, 13, 685-692.	0.7	29
3	Women and Mesothelioma. <i>Chest</i> , 2002, 122, 1885-1886.	0.4	18
4	Potential methods to circumvent blocks in apoptosis in lymphomas. <i>Current Opinion in Oncology</i> , 2002, 14, 490-503.	1.1	11
5	Immunotherapy in the B-cell lymphomas. <i>Cytotherapy</i> , 2002, 4, 439-440.	0.3	0
6	Emerging insights into the biology and therapy of malignant mesothelioma. <i>Seminars in Oncology</i> , 2002, 29, 35-42.	0.8	7
7	Novel Drugs in Development for Malignant Mesothelioma. <i>Clinical Lung Cancer</i> , 2002, 4, 146-148.	1.1	0
8	Pemetrexed (Alimta®): A Novel Antifolate in the Treatment of Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2002, 3, 240-242.	1.1	0
9	Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. <i>Journal of Cellular Physiology</i> , 2002, 193, 37-41.	2.0	7
10	CD20-mediated apoptosis: signalling through lipid rafts. <i>Immunology</i> , 2002, 107, 176-182.	2.0	221
11	Immunotherapy for Lymphomas. <i>International Journal of Hematology</i> , 2003, 77, 444-455.	0.7	29
12	Secondary immune deficiencies associated with biological therapeutics. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 389-395.	2.4	11
13	Desmoplastic malignant mesothelioma of the pleura: Autopsy reveals asbestos exposure. <i>Pathology International</i> , 2003, 53, 401-406.	0.6	16
14	A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. <i>Cancer</i> , 2003, 98, 310-314.	2.0	160
15	The TP53 gene, tobacco exposure, and lung cancer. <i>Human Mutation</i> , 2003, 21, 229-239.	1.1	263
16	TP53 mutations in workers exposed to occupational carcinogens. <i>Human Mutation</i> , 2003, 21, 240-251.	1.1	26
17	Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. <i>International Journal of Cancer</i> , 2003, 106, 160-166.	2.3	65
18	Geographic distribution of incident mesothelioma in Connecticut men, 1990-99. <i>International Journal of Cancer</i> , 2003, 107, 509-510.	2.3	3

#	ARTICLE	IF	CITATIONS
19	Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. <i>Cytometry</i> , 2003, 52A, 101-109.	1.8	39
20	Monoclonal antibody therapy for lymphoma. <i>Blood Reviews</i> , 2003, 17, 143-152.	2.8	34
21	Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 122, 457-464.	1.2	73
22	Clinical use of rituximab in haematological malignancies. <i>British Journal of Cancer</i> , 2003, 89, 1389-1394.	2.9	50
23	A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. <i>Leukemia</i> , 2003, 17, 1384-1389.	3.3	26
24	Use of the Anti-idiotypic Breast Cancer Vaccine 11D10 in Conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 3, S152-S157.	1.1	15
25	Molecular Pathogenesis of Malignant Mesothelioma and its Relationship to Simian Virus 40. <i>Clinical Lung Cancer</i> , 2003, 5, 177-181.	1.1	70
26	Overview of Antibody Therapy in B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, S5-S12.	2.1	6
27	Immunobiological treatments of hairy-cell leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 117-133.	0.7	20
28	Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 281-287.	0.6	28
29	Current controversies regarding the role of asbestos exposure in the causation of malignant mesothelioma: the need for an evidence-based approach to develop medicolegal guidelines. <i>Annals of Diagnostic Pathology</i> , 2003, 7, 321-332.	0.6	31
30	Cyclooxygenase-2 in Lung Cancer. , 2003, 37, 138-162.		39
31	Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). <i>Blood</i> , 2003, 101, 4279-4284.	0.6	483
32	Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Oncology</i> , 2003, 65, 306-310.	0.9	122
33	Clinicopathologic and Molecular Features of Hodgkin Lymphoma. <i>Cancer Biology and Therapy</i> , 2003, 2, 500-507.	1.5	13
34	Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study. <i>Anti-Cancer Drugs</i> , 2003, 14, 809-815.	0.7	9
35	Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S6-S14.	0.6	15
36	Surgical Treatment of Malignant Pleural Mesothelioma*. <i>Chest</i> , 2003, 123, 551-561.	0.4	105

#	ARTICLE	IF	CITATIONS
37	Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. <i>Blood</i> , 2003, 101, 1045-1052.	0.6	353
38	Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2003, 102, 3514-3520.	0.6	125
39	Familial Mesothelioma of the Pleura-A Report of 40 Cases-. <i>Industrial Health</i> , 2004, 42, 235-239.	0.4	30
40	Response to the Letter. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 1046-1047.	1.2	0
41	Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. <i>Cancer Biology and Therapy</i> , 2004, 3, 1217-1224.	1.5	55
42	A Serial Analysis of Gene Expression (SAGE) Database Analysis of Chemosensitivity. <i>Cancer Research</i> , 2004, 64, 2805-2816.	0.4	108
45	Inhibition of the Rafâ€“MEK1/2â€“ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkinâ€™s Lymphoma B Cells by Rituximab. <i>Cancer Research</i> , 2004, 64, 7117-7126.	0.4	188
46	Identification and validation of cell surface antigens for antibody targeting in oncology. <i>Endocrine-Related Cancer</i> , 2004, 11, 659-687.	1.6	109
47	Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells. <i>Cancer Research</i> , 2004, 64, 7479-7485.	0.4	67
48	Handbook of Cancer Vaccines. , 2004, , .		5
49	Treatment of SLE with Anti-CD20 Monoclonal Antibody. , 2004, 8, 193-205.		39
50	Identification and characterization of L985P, a CD20 related family member over-expressed in small cell lung carcinoma. <i>International Journal of Oncology</i> , 2004, 25, 1583.	1.4	4
51	Gene Expression Profiling Identifies Matriptase Overexpression in Malignant Mesothelioma. <i>Chest</i> , 2004, 125, 1843-1852.	0.4	90
52	Loss of RhoB Expression in Human Lung Cancer Progression. <i>Clinical Cancer Research</i> , 2004, 10, 2742-2750.	3.2	158
53	Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. <i>British Journal of Cancer</i> , 2004, 91, 1166-1173.	2.9	65
54	Nursing Considerations for Administering Pemetrexed (Alimta®) in Combination With Cisplatin for Malignant Pleural Mesothelioma. <i>Clinical Journal of Oncology Nursing</i> , 2004, 8, 242-247.	0.3	1
55	Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. <i>The Hematology Journal</i> , 2004, 5, 467-471.	2.0	23
56	Multiple Myeloma: An Overview. <i>Clinical Journal of Oncology Nursing</i> , 2004, 8, 401-405.	0.3	16

#	ARTICLE	IF	CITATIONS
57	Response to the Letter. International Journal of Gynecological Cancer, 2004, 14, 1046-1047.	1.2	0
58	Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen?. Seminars in Cancer Biology, 2004, 14, 399-405.	4.3	24
59	Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer. Seminars in Oncology, 2004, 31, 42-46.	0.8	8
60	Pathogenesis of Malignant Mesothelioma. Clinical Lung Cancer, 2004, 5, S46-S50.	1.1	22
61	Pemetrexed Alone and in Combination with Platinum Compounds in the Management of Malignant Mesothelioma. Clinical Lung Cancer, 2004, 5, S56-S60.	1.1	1
62	Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. European Journal of Pharmacology, 2004, 498, 9-18.	1.7	43
63	Rituximab-Induced Tumor Progression: Does It Really Happen?. Medical Oncology, 2004, 21, 205-206.	1.2	10
64	Contested Etiology and Fragile Castles: An Ethnography of Cancer Risk and Cancer Research in Two Parts. Culture, Medicine and Psychiatry, 2004, 28, 311-314.	0.7	1
65	Remarkable response to rituximab in a patient with atypical CD20 ++ mantle cell lymphoma of the bone marrow leading to severe pancytopenia. Annals of Hematology, 2004, 83, 316-318.	0.8	3
66	Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Annals of Hematology, 2004, 83, 634-45.	0.8	104
67	Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer, 2004, 101, 139-145.	2.0	131
68	Investigation of simian virus 40 large T antigen in 18 autopsied malignant mesothelioma patients in Japan. Journal of Medical Virology, 2004, 74, 668-676.	2.5	17
69	Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1274-1287.	0.4	70
70	Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments. Critical Reviews in Oncology/Hematology, 2004, 50, 101-109.	2.0	16
71	Malignant pleural mesothelioma. Current Problems in Cancer, 2004, 28, 93-174.	1.0	78
72	Malignant pleural mesothelioma: overview of the North American and European experience. Thoracic Surgery Clinics, 2004, 14, 435-445.	0.4	24
73	Genetics of malignant pleural mesothelioma: molecular markers and biologic targets. Thoracic Surgery Clinics, 2004, 14, 461-468.	0.4	7
74	Monoclonal Antibody 16D10 to the C-Terminal Domain of the Feto-Acinar Pancreatic Protein Binds to Membrane of Human Pancreatic Tumoral SOJ-6 Cells and Inhibits the Growth of Tumor Xenografts. Neoplasia, 2004, 6, 713-724.	2.3	15

#	ARTICLE	IF	CITATIONS
75	Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG*1. <i>International Immunopharmacology</i> , 2004, 4, 1117-1117.	1.7	0
76	Role of asbestos in etiology of malignant pleural mesothelioma. <i>Thoracic Surgery Clinics</i> , 2004, 14, 479-487.	0.4	21
77	Evidence of an important role for SV40 in mesothelioma. <i>Thoracic Surgery Clinics</i> , 2004, 14, 489-495.	0.4	21
78	Treatment Options in Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 155-162.	2.1	5
79	Epidemiology, biologic behavior, and natural history of mesothelioma. <i>Thoracic Surgery Clinics</i> , 2004, 14, 469-477.	0.4	59
80	Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. <i>Current Opinion in Pharmacology</i> , 2004, 4, 398-402.	1.7	79
81	Rituximab in autoimmune diseases. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 299-309.	2.5	42
82	Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. <i>International Immunopharmacology</i> , 2004, 4, 1117-1124.	1.7	30
83	Management of Autoimmune Hemolytic Anemias. , 2004, , 401-458.		12
84	<title>Use of OCT to study tumor cell growth in 3D membranes</title>. , 2004, , .		1
85	Malignant Pleural Mesotheliomaâ€”An Update. <i>International Journal of Occupational and Environmental Health</i> , 2004, 10, 26-39.	1.2	18
86	Cutaneous Immunocytoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2004, 12, 216-224.	0.6	20
87	Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. <i>Blood</i> , 2004, 104, 1166-1173.	0.6	122
88	Malignant Pleural Mesothelioma. <i>American Journal of the Medical Sciences</i> , 2005, 329, 29-44.	0.4	43
89	Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2005, 11, S45-S54.	0.5	30
90	Hypofractionated Accelerated Radiotherapy With Cytoprotection Combined With Trastuzumab, Liposomal Doxorubicine, and Docetaxel in c-erbB-2???Positive Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 495-500.	0.6	25
91	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-Î±/Î²â€”inducible gene expression, without significant toxicity. <i>Blood</i> , 2005, 105, 489-495.	0.6	155
92	Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. <i>Blood</i> , 2005, 106, 1164-1174.	0.6	194

#	ARTICLE	IF	CITATIONS
93	Acute Tumor Lysis Syndrome Induced by Rituximab in Diffuse Large B-Cell Lymphoma. <i>International Journal of Hematology</i> , 2005, 82, 312-314.	0.7	22
94	Pleural mesothelioma with extension into the thoracic spinal cord. <i>Internal Medicine Journal</i> , 2005, 35, 195-196.	0.5	9
95	Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. <i>British Journal of Cancer</i> , 2005, 93, 319-330.	2.9	69
96	Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets. <i>Seminars in Oncology</i> , 2005, 32, 19-26.	0.8	21
97	Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 393-400.	0.4	18
98	Normativa sobre el asbesto y sus enfermedades pleuropulmonares. <i>Archivos De Bronconeumologia</i> , 2005, 41, 153-168.	0.4	20
100	Clinical Studies of Immunotherapy With Rituximab (Rituxan®) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®) in B-Cell Lymphoid Malignancies. , 2005, , 677-709.		0
101	Microarray analysis and RNA silencing to determine genes functionally important in mesothelioma. , 2005, , 447-469.		0
102	Targeted $\alpha$ -Particle Therapy. , 2005, , 107-131.		0
103	Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer. <i>Cancer Research</i> , 2005, 65, 10562-10568.	0.4	120
104	Milk Casein-Based Diet Containing TGF $\beta$ 2 Controls the Inflammatory Reaction in the HLA-B*27 Transgenic Rat Model. <i>Journal of Parenteral and Enteral Nutrition</i> , 2005, 29, S141-8; discussion S149-50, S184-8.	1.3	21
105	Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 4390-4398.	0.8	143
106	Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 835-842.	1.9	49
107	Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2005, 11, 7151s-7157s.	3.2	21
108	2-Cyano-3,12-dioxoleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer. <i>Journal of Biological Chemistry</i> , 2005, 280, 36273-36282.	1.6	100
109	Invasive Epithelial Mesothelioma in a Dog. <i>Veterinary Pathology</i> , 2005, 42, 77-81.	0.8	34
110	Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4079-4088.	0.8	899
111	Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance. <i>Clinical Cancer Research</i> , 2005, 11, 4305-4315.	3.2	41

#	ARTICLE	IF	CITATIONS
112	Multigene Targeting with Antisense Oligodeoxynucleotides: An Exploratory Study Using Primary Human Leukemia Cells. <i>Clinical Cancer Research</i> , 2005, 11, 4948-4954.	3.2	20
113	Combination therapy for advanced pancreatic cancer using Herceptin <sup>®</sup> , <sup>†</sup> plus chemotherapy. <i>International Journal of Oncology</i> , 2005, 27, 1125.	1.4	7
114	Molecular Biology of Malignant Mesothelioma: A Review. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 997-1023.	0.9	15
115	Treatment of primary cutaneous B-cell lymphoma with rituximab. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 847-853.	0.6	89
116	Preventing radiation induced xerostomia. <i>Cancer Treatment Reviews</i> , 2005, 31, 546-554.	3.4	25
118	Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. <i>Gastroenterology</i> , 2005, 128, 1642-1654.	0.6	142
119	Monoclonal antibodies in the treatment of indolent lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 69-80.	0.7	10
120	What is remission in follicular lymphoma and what is its relevance?. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 27-56.	0.7	24
121	Radio-immunotherapy in low-grade non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 81-95.	0.7	13
122	Clinical significance of biological differences between cavitated and solid form of squamous cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 171-179.	0.9	22
123	Molecular prognostic markers in malignant mesothelioma. <i>Lung Cancer</i> , 2005, 49, S53-S60.	0.9	27
124	Apoptosis regulation and drug resistance in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2005, 49, S105-S108.	0.9	6
125	Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. <i>Arthritis Research and Therapy</i> , 2006, 8, R83.	1.6	265
126	p53-Induced Apoptosis Occurs in the Absence of p14ARF in Malignant Pleural Mesothelioma. <i>Neoplasia</i> , 2006, 8, 551-559.	2.3	40
127	Biologic, Cytogenetic, and Molecular Factors in Mesothelial Proliferations. <i>Ultrastructural Pathology</i> , 2006, 30, 19-30.	0.4	9
129	The pathogenesis of mesothelioma. <i>Seminars in Diagnostic Pathology</i> , 2006, 23, 56-60.	1.0	66
130	Evaluation of Suspected Monoclonal Gammopathies: Experience in a Tertiary Care Hospital. <i>Medical Journal Armed Forces India</i> , 2006, 62, 134-137.	0.3	9
131	New Therapies for Systemic Lupus Erythematosus: Cellular Targets. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 201-215.	0.8	16



#	ARTICLE	IF	CITATIONS
132	B Cells in Health and Disease. Mayo Clinic Proceedings, 2006, 81, 377-384.	1.4	38
133	Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clinical Lymphoma and Myeloma, 2006, 6, 423-426.	1.4	11
134	Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?. Journal of Cardiothoracic Surgery, 2006, 1, 39.	0.4	0
135	Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2006, 19, 701-713.	0.7	27
136	Mesothelioma in patients with nonoccupational asbestos exposure. Annals of Diagnostic Pathology, 2006, 10, 241-250.	0.6	13
137	The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Letters, 2006, 233, 328-337.	3.2	34
138	Biology and management of malignant pleural mesothelioma. European Journal of Cancer, 2006, 42, 2706-2714.	1.3	64
139	Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. Journal of the American Academy of Dermatology, 2006, 55, 449-459.	0.6	71
140	Marcadores morfológicos de prognóstico no mesotelioma maligno: um estudo de 58 casos. Jornal Brasileiro De Pneumologia, 2006, 32, 322-332.	0.4	3
141	Evolving Aspects of Mesothelioma Carcinogenesis: SV40 and Genetic Predisposition. Journal of Thoracic Oncology, 2006, 1, 169-171.	0.5	4
142	High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice. Anti-Cancer Drugs, 2006, 17, 685-695.	0.7	6
143	Mineral-Induced Lung Disease in Modern Industry. Clinical Pulmonary Medicine, 2006, 13, 91-102.	0.3	0
144	Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver International, 2006, 26, 625-629.	1.9	58
145	Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. British Journal of Haematology, 2006, 132, 42-55.	1.2	27
146	Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. British Journal of Haematology, 2006, 135, 33-42.	1.2	42
147	Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Science, 2006, 97, 72-79.	1.7	55
148	Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan. Cancer Science, 2006, 97, 292-295.	1.7	23
149	The management of acquired haemophilia. Haemophilia, 2006, 12, 32-36.	1.0	21

#	ARTICLE	IF	CITATIONS
150	Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. <i>Oncogene</i> , 2006, 25, 5960-5968.	2.6	162
151	Three Cases of Activation of Cutaneous Squamous-cell Carcinoma During Treatment with Prolonged Administration of Rituximab. <i>Clinical Oncology</i> , 2006, 18, 155-156.	0.6	18
152	The Implementation of PET in Non-small-cell Lung Cancer in the Netherlands. <i>Clinical Oncology</i> , 2006, 18, 156-157.	0.6	5
153	Cytogenetic and molecular genetic changes in malignant mesothelioma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 170, 9-15.	1.0	90
154	Immunotherapy for Cancer with Special Reference to Lung Cancer. <i>Apollo Medicine</i> , 2006, 3, 277-284.	0.0	2
155	Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. <i>International Journal of Cancer</i> , 2006, 119, 1303-1311.	2.3	104
156	Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. <i>Muscle and Nerve</i> , 2006, 33, 575-580.	1.0	112
157	Identification of Candidate Target Antigens for Antibody-Based Immunotherapy in Childhood B-Cell Precursor ALL. <i>Klinische Padiatrie</i> , 2006, 218, 327-333.	0.2	28
158	Genetic Predisposition to Fiber Carcinogenesis Causes a Mesothelioma Epidemic in Turkey. <i>Cancer Research</i> , 2006, 66, 5063-5068.	0.4	156
159	Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. <i>Clinical Cancer Research</i> , 2006, 12, 4027-4035.	3.2	217
160	Use of Urine Flow Cytometry to Verify Relapse of Burkitt's Lymphoma in the Genitourinary System. <i>Journal of Clinical Oncology</i> , 2006, 24, 4515-4516.	0.8	7
161	Tumeurs rares du tube digestif et du pÃ©ritoine. , 2006, , 241-270.		0
162	The biology and treatment of chronic lymphocytic leukemia. <i>Annals of Oncology</i> , 2006, 17, x144-x154.	0.6	23
163	Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review. <i>Leukemia and Lymphoma</i> , 2006, 47, 2584-2589.	0.6	33
165	Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2007, 67, 9903-9912.	0.4	35
166	Bortezomib Inhibits Nuclear Factor-Î²-Dependent Survival and Has Potent In vivo Activity in Mesothelioma. <i>Clinical Cancer Research</i> , 2007, 13, 5942-5951.	3.2	90
167	SV40 Oncoproteins Enhance Asbestos-Induced DNA Double-Strand Breaks and Abrogate Senescence in Murine Mesothelial Cells. <i>Cancer Research</i> , 2007, 67, 3637-3645.	0.4	41
168	Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 257-273.	1.1	24

#	ARTICLE	IF	CITATIONS
169	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1102-1109.	0.6	63
170	Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine. <i>Cancer Research</i> , 2007, 67, 10939-10947.	0.4	86
171	The clinical use of antibodies in haematological malignancies. <i>Annals of Oncology</i> , 2007, 18, ix51-ix57.	0.6	8
172	Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 634-8.	1.4	24
173	Glycoengineering of Î±Gal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope. <i>Glycobiology</i> , 2007, 17, 620-630.	1.3	7
174	MESOMARKâ„¢: A Potential Test for Malignant Pleural Mesothelioma. <i>Clinical Chemistry</i> , 2007, 53, 666-672.	1.5	127
175	Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 802-810.	1.9	24
176	Complete Response to Temozolomide Treatment in an Elderly Patient With Recurrent Primary Central Nervous System Lymphoma-Case Report-. <i>Neurologia Medico-Chirurgica</i> , 2007, 47, 229-232.	1.0	6
177	Keynote Lecture in the 13th Japanese Society of Immunotoxicology (JSIT 2006). <i>Environmental Health and Preventive Medicine</i> , 2007, 12, 153-160.	1.4	0
178	PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. <i>Blood</i> , 2007, 109, 1712-1719.	0.6	19
179	Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 148-153.	0.6	82
180	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007, 370, 1861-1874.	6.3	859
182	Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2110-2120.	0.6	16
183	Rapid improvement of hypoxemia by the use of rituximab in patients with pulmonary intravascular lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 197-200.	0.6	6
184	Lung Cancer in Never Smokers: A Review. <i>Journal of Clinical Oncology</i> , 2007, 25, 561-570.	0.8	587
185	Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies. <i>Leukemia and Lymphoma</i> , 2007, 48, 1828-1834.	0.6	12
186	The Impact of Comorbid Atopic Disease on Asthma: Clinical Expression and Treatment. <i>Journal of Asthma</i> , 2007, 44, 149-161.	0.9	18
187	Epidemiology of peritoneal mesothelioma: a review. <i>Annals of Oncology</i> , 2007, 18, 985-990.	0.6	235

#	ARTICLE	IF	CITATIONS
189	Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. <i>Molecular Cancer</i> , 2007, 6, 66.	7.9	57
190	Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. <i>International Journal of Cancer</i> , 2007, 120, 2739-2743.	2.3	53
191	Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. <i>Oncogene</i> , 2007, 26, 3704-3713.	2.6	93
192	Intraocular rituximab. <i>Eye</i> , 2007, 21, 1453-1454.	1.1	8
193	Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. <i>Cancer Science</i> , 2007, 98, 438-446.	1.7	86
194	Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. <i>Journal of the Peripheral Nervous System</i> , 2007, 12, 102-107.	1.4	98
195	Evaluation of simian virus 40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. <i>Pathology International</i> , 2007, 57, 493-501.	0.6	18
196	Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. <i>European Journal of Haematology</i> , 2007, 79, 546-549.	1.1	12
197	Keynote lecture in the 13th Japanese Society of Immunotoxicology (JSIT 2006). <i>Environmental Health and Preventive Medicine</i> , 2007, 12, 153-60.	1.4	2
198	Exchanging human Fc $\gamma$ 1 with murine Fc $\gamma$ 2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 459-468.	2.0	12
199	Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?. <i>Pediatric Nephrology</i> , 2007, 22, 893-898.	0.9	50
200	Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic "pathologic" clinical correlations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 455-470.	1.2	15
201	Erionite series minerals: mineralogical and carcinogenic properties. <i>Environmental Geochemistry and Health</i> , 2008, 30, 367-381.	1.8	48
202	Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis. <i>Current Treatment Options in Oncology</i> , 2008, 9, 147-157.	1.3	207
203	Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma. <i>Internal and Emergency Medicine</i> , 2008, 3, 161-163.	1.0	9
204	Targeted Biologic Approaches to the Treatment of Systemic Vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 35, 79-87.	2.9	3
205	Molecular biology of malignant mesothelioma. <i>Environmental Health and Preventive Medicine</i> , 2008, 13, 65-70.	1.4	31
206	Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008, 27, 1343-1353.	1.0	33

#	ARTICLE	IF	CITATIONS
207	Post-marketing safety of antineoplastic monoclonal antibodies: rituximab and trastuzumab. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 714-721.	0.9	25
208	Rituximab therapy for chronic lymphocytic leukaemia. <i>Future Prescriber</i> , 2008, 9, 11-15.	0.1	0
209	Cytoprotection for Radiation-Associated Normal Tissue Injury. <i>Cancer Treatment and Research</i> , 2008, , 302-322.	0.2	3
210	Amifostine prior to lethal irradiation prevents allogeneic bone marrow engraftment in mice. <i>Bone Marrow Transplantation</i> , 2008, 41, 927-934.	1.3	4
211	Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA <sub>1</sub> and LPA <sub>2</sub> . <i>Cancer Science</i> , 2008, 99, 1603-1610.	1.7	20
212	A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. <i>British Journal of Haematology</i> , 2008, 142, 394-403.	1.2	20
213	Emerging drugs for rheumatoid arthritis. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 175-196.	1.0	20
214	Therapy in Neuromuscular Diseases. , 2008, , 77-92.		0
215	Anti-CD20 Monoclonal Antibody in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Handbook of Experimental Pharmacology</i> , 2008, , 163-181.	0.9	9
216	New treatment options for immune-mediated hematological disorders. <i>European Journal of Internal Medicine</i> , 2008, 19, 579-586.	1.0	4
217	Antibody and Immunomodulatory Agents in the Treatment of Indolent Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2008, 45, 85-89.	1.8	6
218	Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 2116-2124.	0.6	11
219	Modulation of CD59 Expression by Restrictive Silencer Factor-Derived Peptides in Cancer Immunotherapy for Neuroblastoma. <i>Cancer Research</i> , 2008, 68, 5979-5987.	0.4	27
220	The Potential Effect of Statins on Rituximab Immunotherapy. <i>PLoS Medicine</i> , 2008, 5, e77.	3.9	7
221	Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. <i>Journal of Carcinogenesis</i> , 2008, 7, 3.	2.5	4
222	GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2008, 49, 1681-1692.	0.6	19
223	Opposite Effects of Notch-1 and Notch-2 on Mesothelioma Cell Survival under Hypoxia Are Exerted through the Akt Pathway. <i>Cancer Research</i> , 2008, 68, 9678-9685.	0.4	111
224	The effect of azacitidine on interleukin-6 signaling and nuclear factor- $\kappa$ B activation and its in vitro and in vivo activity against multiple myeloma. <i>Haematologica</i> , 2008, 93, 860-869.	1.7	43

#	ARTICLE	IF	CITATIONS
225	Survival and Prognostic Factors of Unresectable Pancreatic Cancer. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 86-91.	1.1	62
226	Protein kinase C beta in malignant pleural mesothelioma. <i>Anti-Cancer Drugs</i> , 2008, 19, 841-848.	0.7	11
227	Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma. <i>Yonsei Medical Journal</i> , 2008, 49, 155.	0.9	21
228	Asbestos Burden Predicts Survival in Pleural Mesothelioma. <i>Environmental Health Perspectives</i> , 2008, 116, 723-726.	2.8	27
229	Allylmethylsulfide Down-Regulates X-Ray Irradiation-Induced Nuclear Factor- $\kappa$ B Signaling in C57/BL6 Mouse Kidney. <i>Journal of Medicinal Food</i> , 2009, 12, 542-551.	0.8	9
230	Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. <i>Molecular Medicine Reports</i> , 2009, 2, 181-8.	1.1	41
231	MET/PKC $\alpha$ expression correlate with metastasis and inhibition is synergistic in lung cancer. <i>Journal of Carcinogenesis</i> , 2009, 8, 15.	2.5	1
232	Update on immunotherapy for systemic lupus erythematosus—what's hot and what's not!. <i>Rheumatology</i> , 2009, 48, 332-341.	0.9	53
233	Human-Like Mouse Models for Testing the Efficacy and Safety of Anti- $\lambda$ 2-Microglobulin Monoclonal Antibodies to Treat Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 951-959.	3.2	19
234	Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. <i>Autoimmunity Reviews</i> , 2009, 8, 552-557.	2.5	9
235	Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. <i>American Journal of Hematology</i> , 2009, 84, 553-559.	2.0	135
236	<i>CDKN2A</i> , <i>NF2</i> , and <i>JUN</i> are dysregulated among other genes by miRNAs in malignant mesothelioma—A miRNA microarray analysis. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 615-623.	1.5	248
237	Current treatments of chronic immune-mediated demyelinating polyneuropathies. <i>Muscle and Nerve</i> , 2009, 39, 563-578.	1.0	77
238	Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 15-27.	1.2	45
239	Clinical impact of radiotherapy for locally advanced pancreatic cancer. <i>Journal of Gastroenterology</i> , 2009, 44, 1209-1214.	2.3	10
240	Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature. <i>Pediatric Pulmonology</i> , 2009, 44, 922-934.	1.0	48
241	Estimating the incidence of lung cancer attributable to occupational exposure in Iran. <i>Population Health Metrics</i> , 2009, 7, 7.	1.3	16
242	The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. <i>European Journal of Cancer Care</i> , 2009, 18, 116-123.	0.7	14

#	ARTICLE	IF	CITATIONS
243	Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. <i>Leukemia</i> , 2009, 23, 457-466.	3.3	13
244	Hypofractionated and Accelerated Radiotherapy With Subcutaneous Amifostine Cytoprotection as Short Adjuvant Regimen After Breast-Conserving Surgery: Interim Report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1173-1180.	0.4	14
245	Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 498-503.	0.8	168
246	Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. <i>European Journal of Surgical Oncology</i> , 2009, 35, 980-985.	0.5	41
247	A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. <i>Life Sciences</i> , 2009, 84, 650-656.	2.0	30
248	Treating severe systemic lupus erythematosus with rituximab. An open study. <i>ReumatologÃa ClÃnica</i> , 2009, 5, 147-152.	0.2	18
249	Functional inactivation of NF2/merlin in human mesothelioma. <i>Lung Cancer</i> , 2009, 64, 140-147.	0.9	139
250	Treating severe systemic lupus erythematosus with rituximab. An open study. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2009, 5, 147-152.	0.2	6
251	[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2009, 50, 904-911.	0.6	16
252	Mesothelioma: Path to Multimodality Treatment. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2009, 21, 125-131.	0.4	10
253	Recombinant. , 2008, , 2573-2573.		0
254	Activated Tâ€cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2009, 32, 737-743.	1.2	49
255	Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. <i>Blood</i> , 2009, 114, 5007-5015.	0.6	79
256	Rituximab for Intraocular Lymphoma. <i>Retina</i> , 2009, 29, 129-132.	1.0	66
257	The autophylic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis. <i>Anti-Cancer Drugs</i> , 2010, 21, 532-542.	0.7	7
258	Therapeutic (High) Doses of Rituximab Activate Calcium Mobilization and Inhibit B-cell Growth via an Unusual Mechanism Triggered Independently of Both CD20 and FcÎ³ Receptors. <i>Journal of Immunotherapy</i> , 2010, 33, 30-39.	1.2	5
259	Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. <i>Oncology Reports</i> , 2010, 24, 423-31.	1.2	40
260	Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy. <i>Annals of Hematology</i> , 2010, 89, 985-991.	0.8	22



#	ARTICLE	IF	CITATIONS
261	Impact of Human IgA Antibodies on Complement-Dependent Cytotoxicity Mediated by Combinations of EGF-R-Directed Antibodies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 303-312.	1.0	9
262	Impact of Tumor Angiogenesis in Peritoneal Mesothelioma After Radical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Pathology and Oncology Research</i> , 2010, 16, 217-222.	0.9	9
263	Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. <i>Autoimmunity Highlights</i> , 2010, 1, 87-94.	3.9	27
264	9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence <i>in situ</i> hybridization analysis. <i>Pathology International</i> , 2010, 60, 395-399.	0.6	72
265	B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. <i>Experimental Hematology</i> , 2010, 38, 213-221.	0.2	35
266	The tocotrienol-rich fraction from rice bran enhances cisplatin-induced cytotoxicity in human mesothelioma H28 cells. <i>Phytotherapy Research</i> , 2010, 24, 1317-1321.	2.8	25
267	Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. <i>Cancer Science</i> , 2010, 101, 1-6.	1.7	92
268	Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 37-46.	1.2	43
269	Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. <i>ClinicoEconomics and Outcomes Research</i> , 2010, 2, 37.	0.7	3
270	Rituximab for the treatment of patients with chronic lymphocytic leukemia. <i>Cancer Management and Research</i> , 2010, 2, 71.	0.9	4
271	Signaling Targets in Lymphoid Leukemias. , 2010, , 2831-2835.		0
272	Managing HBV in patients with impaired immunity. <i>Gut</i> , 2010, 59, 1430-1445.	6.1	63
273	The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. <i>Free Radical Research</i> , 2010, 44, 529-540.	1.5	28
274	Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Proinflammatory Cytokines and Therapeutic Approaches. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-13.	3.0	37
275	Diffusion-Weighted MRI of Malignant Pleural Mesothelioma: Preliminary Assessment of Apparent Diffusion Coefficient in Histologic Subtypes. <i>American Journal of Roentgenology</i> , 2010, 195, W125-W130.	1.0	79
276	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. <i>Annals of Oncology</i> , 2010, 21, 1217-1221.	0.6	22
277	The role of radiotherapy in locally advanced pancreatic carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 437-447.	8.2	36
278	B-cell Biology and Related Therapies in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 109-130.	0.8	20



#	ARTICLE	IF	CITATIONS
279	Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer, 2010, 70, 146-151.	0.9	31
280	Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S27-S33.	0.2	3
281	The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opinion on Drug Delivery, 2010, 7, 461-478.	2.4	74
283	Merkel cell polyomavirus is not detected in mesotheliomas. Journal of Clinical Virology, 2010, 47, 196-198.	1.6	15
284	Management of malignant pleural mesothelioma. Thoracic Cancer, 2010, 1, 53-61.	0.8	2
285	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, The, 2010, 376, 1164-1174.	6.3	1,713
286	Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leukemia and Lymphoma, 2011, 52, 360-373.	0.6	28
288	RAEB. , 2011, , 3160-3160.		0
291	Receptor Tyrosine Kinases. , 2011, , 3198-3203.		0
292	Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network. American Journal of Pathology, 2011, 179, 1483-1493.	1.9	54
293	Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases. Annals of Diagnostic Pathology, 2011, 15, 25-29.	0.6	30
294	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews, 2011, 37, 533-542.	3.4	31
295	Rituximab in Hodgkin lymphoma: Is the target always a hit?. Cancer Treatment Reviews, 2011, 37, 385-390.	3.4	38
296	Advances in the biology of malignant pleural mesothelioma. Cancer Treatment Reviews, 2011, 37, 543-558.	3.4	94
297	Toxicoproteomic evaluation of carbon nanomaterials in vitro. Journal of Proteomics, 2011, 74, 2703-2712.	1.2	15
298	Cancer broncho-pulmonaire chez le non-fumeur. , 2011, , 163-194.		0
299	Bowman-Birk protease inhibitor from soybeans enhances cisplatin-induced cytotoxicity in human mesothelioma cells. Experimental and Therapeutic Medicine, 2011, 2, 719-724.	0.8	5
300	Erionite in Road Gravel Associated With Interstitial and Pleural Changesâ€”An Occupational Hazard in Western United States. Journal of Occupational and Environmental Medicine, 2011, 53, 892-898.	0.9	33

#	ARTICLE	IF	CITATIONS
301	Autoimmunity associated with immunotherapy of cancer. <i>Blood</i> , 2011, 118, 499-509.	0.6	163
302	Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. <i>Pathology International</i> , 2011, 61, 331-344.	0.6	72
303	Rituximab in chronic lymphocytic leukemia. <i>Advances in Therapy</i> , 2011, 28, 534-554.	1.3	12
304	Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin. <i>Science China Life Sciences</i> , 2011, 54, 255-262.	2.3	6
305	Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. <i>Cancer</i> , 2011, 117, 5234-5244.	2.0	100
306	Effects of formulation and route of administration on the systemic availability of Exâ€RAD<sup>Â®</sup>, a new radioprotectant, in preclinical species. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 99-111.	1.1	9
307	Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 243-249.	0.9	43
308	Prognostic significance of neuron-specific enolase in patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1697-1703.	0.6	5
309	Disseminated sclerosing peritoneal mesothelioma in a dog. <i>Journal of Veterinary Diagnostic Investigation</i> , 2011, 23, 1046-1050.	0.5	18
310	Mesothelioma: an update. <i>Breathe</i> , 2011, , 45-52.	0.6	3
311	Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , 2011, 87, 223-238.	0.9	3
312	Monoclonal antibodies in hematological malignancies: Past, present and future. <i>Journal of Cancer Research and Therapeutics</i> , 2011, 7, 399.	0.3	16
313	Galiximab Signals B-NHL Cells and Inhibits the Activities of NF-Î®-Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoimmunotherapeutic Drugs. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 572-581.	1.9	20
314	Mesothelioma Not Associated With Asbestos Exposure. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 262-267.	1.2	61
315	Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. <i>Journal of Clinical Pathology</i> , 2012, 65, 77-82.	1.0	34
316	Development of Enteroviral Aseptic Meningitis After Rituximab Treatment of Non-Hodgkin Lymphoma. <i>Infectious Diseases in Clinical Practice</i> , 2012, 20, 291-293.	0.1	2
317	Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation. <i>Clinical Cancer Research</i> , 2012, 18, 1568-1577.	3.2	35
318	Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. <i>Journal of Clinical Pathology</i> , 2012, 65, 522-527.	1.0	26

#	ARTICLE	IF	CITATIONS
319	Malignant pleural mesothelioma. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 377-385.	0.5	16
320	A Case Report of an Extremely Rare and Aggressive Tumor: Primary Malignant Pericardial Mesothelioma. <i>Rare Tumors</i> , 2012, 4, 67-70.	0.3	13
321	Clinical Aspects of Monoclonal B-Cell Lymphocytosis. <i>Cancer Control</i> , 2012, 19, 8-17.	0.7	25
322	Diagnosis and Treatment of Rituximab-Induced Acute Tumor Lysis Syndrome in Patients With Diffuse Large B-Cell Lymphoma. <i>American Journal of the Medical Sciences</i> , 2012, 343, 337-341.	0.4	22
323	Yes is a central mediator of cell growth in malignant mesothelioma cells. <i>Oncology Reports</i> , 2012, 28, 1889-1893.	1.2	25
324	YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. <i>Oncogene</i> , 2012, 31, 5117-5122.	2.6	237
325	Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. <i>Critical Care</i> , 2012, 16, 231.	2.5	138
326	OccIDEAS: An Innovative Tool to Assess Past Asbestos Exposure in the Australian Mesothelioma Registry. <i>Safety and Health at Work</i> , 2012, 3, 71-76.	0.3	15
327	Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 171-173.	1.6	3
328	Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. <i>British Journal of Pharmacology</i> , 2012, 166, 532-553.	2.7	19
329	Chemoimmunotherapy in acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2012, 26, 25-32.	2.8	84
330	Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. <i>Journal of Biomedical Science</i> , 2012, 19, 60.	2.6	78
331	Arsenic, asbestos and radon: emerging players in lung tumorigenesis. <i>Environmental Health</i> , 2012, 11, 89.	1.7	60
332	Clinical and biologic prognostic factors in malignant pleural mesothelioma. <i>Thoracic Cancer</i> , 2012, 3, 289-302.	0.8	9
333	Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2012, 77, 192-198.	0.9	64
334	Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. <i>Cancer Gene Therapy</i> , 2012, 19, 218-228.	2.2	27
335	Malignant Pleural Mesothelioma: From the Bench to the Bedside. <i>Respiration</i> , 2012, 83, 481-493.	1.2	48
336	Thyroid Eye Disease: Towards an Evidence Base for Treatment in the 21st Century. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 318-324.	2.0	36

#	ARTICLE	IF	CITATIONS
337	Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. <i>Experimental and Molecular Pathology</i> , 2012, 93, 154-161.	0.9	17
338	A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. <i>Pathology International</i> , 2012, 62, 226-231.	0.6	15
339	Malignant mesothelioma: Facts, Myths, and Hypotheses. <i>Journal of Cellular Physiology</i> , 2012, 227, 44-58.	2.0	314
340	Pathological and molecular biological approaches to early mesothelioma. <i>International Journal of Clinical Oncology</i> , 2012, 17, 40-47.	1.0	24
341	PTEN protein expression in malignant pleural mesothelioma. <i>Tumor Biology</i> , 2013, 34, 847-851.	0.8	20
342	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	2
343	EphB4 as a therapeutic target in mesothelioma. <i>BMC Cancer</i> , 2013, 13, 269.	1.1	28
344	Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma. <i>Archives of Medical Research</i> , 2013, 44, 549-554.	1.5	11
345	Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines. <i>Cancer Genetics</i> , 2013, 206, 191-205.	0.2	23
346	A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy. <i>Journal of the Neurological Sciences</i> , 2013, 326, 1-9.	0.3	10
347	El mesotelioma pericrdico existe. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2013, 20, 239-241.	0.0	0
348	Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 279-283.	0.5	12
349	Gene therapy for malignant mesothelioma: Current prospects and challenges. <i>Cancer Gene Therapy</i> , 2013, 20, 150-156.	2.2	27
350	Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2013, 108, 1743-1749.	2.9	39
351	New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 131-137.	0.9	15
352	Reliability of Family Proxy Data for Studies of Malignant Mesothelioma: Results from the ATSDR Pilot Surveillance. <i>ISRN Oncology</i> , 2013, 2013, 1-5.	2.1	0
353	CD90 Is a Diagnostic Marker to Differentiate Between Malignant Pleural Mesothelioma and Lung Carcinoma With Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2013, 140, 544-549.	0.4	14
354	RETINAL TOXICITY OF INTRAVITREAL RITUXIMAB IN ALBINO RABBITS. <i>Retina</i> , 2013, 33, 649-656.	1.0	4

#	ARTICLE	IF	CITATIONS
355	miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma. <i>Chest</i> , 2013, 144, 1632-1643.	0.4	50
356	Differences in Transcript Levels of ABC Transporters Between Pancreatic Adenocarcinoma and Nonneoplastic Tissues. <i>Pancreas</i> , 2013, 42, 707-716.	0.5	94
357	Mesothelioma: An Evidence-Based Review. , 2013, , .		0
358	A Retrospective Study of Palliative Cisplatin-Based Doublet Chemotherapy for Malignant Pleural Mesothelioma. <i>Cancer and Clinical Oncology</i> , 2014, 3, .	0.2	0
359	CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. <i>Oncotarget</i> , 2014, 5, 6191-6205.	0.8	13
360	Perspectives on refractory ceramic fiber (RCF) carcinogenicity: comparisons with other fibers. <i>Inhalation Toxicology</i> , 2014, 26, 789-810.	0.8	26
361	Childhood and Adolescent B-Cell Lymphoma: Bench to Bedside and Back to Bench. , 2014, , 247-285.		0
362	Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 998-1007.	0.5	82
363	Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. <i>Leukemia and Lymphoma</i> , 2014, 55, 1609-1617.	0.6	38
364	Rituximab in idiopathic nephrotic syndrome: does it make sense?. <i>Pediatric Nephrology</i> , 2014, 29, 1313-1319.	0.9	9
365	Effects of amifostine on endometriosis, comparison with N-acetyl cysteine, and leuprolide as a new treatment alternative: a randomized controlled trial. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 193-200.	0.8	12
366	The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey. <i>Environmental Geochemistry and Health</i> , 2014, 36, 55-64.	1.8	17
367	Mechanisms of Immunosuppressive Drugs. , 2014, , 127-141.		2
368	Role of microRNAs in malignant mesothelioma. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2865-2878.	2.4	31
370	Identification of actionable mutations in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 86, 35-40.	0.9	26
371	Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1715-1724.	0.6	22
372	CREB-Induced Inflammation Is Important for Malignant Mesothelioma Growth. <i>American Journal of Pathology</i> , 2014, 184, 2816-2827.	1.9	29
373	SV40 TAg mouse models of cancer. <i>Seminars in Cell and Developmental Biology</i> , 2014, 27, 61-73.	2.3	21

#	ARTICLE	IF	CITATIONS
374	Characterization of SM201, an anti-hFc $\gamma$ RIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells. <i>Immunology Letters</i> , 2014, 160, 145-150.	1.1	15
375	A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. <i>SpringerPlus</i> , 2015, 4, 358.	1.2	6
376	Practical experience with rituximab subcutaneous. <i>Cancer Nursing Practice</i> , 2015, 14, 29-37.	0.2	1
377	Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. <i>Cancer Management and Research</i> , 2015, 7, 319.	0.9	3
378	Clinical and Prognostic Features of Erionite-Induced Malignant Mesothelioma. <i>Yonsei Medical Journal</i> , 2015, 56, 311.	0.9	17
379	Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets. <i>Cureus</i> , 2015, 7, e376.	0.2	16
380	The Emerging Role of Rituximab in Autoimmune Blistering Diseases. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 167-177.	3.3	10
381	Rituximab preserves vision in ocular mucous membrane pemphigoid. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 927-933.	1.4	28
382	Monoclonal Antibodies for Cancer Immunotherapy. , 2015, , 293-328.		6
383	The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma. <i>Turkish Journal of Medical Sciences</i> , 2015, 45, 607-614.	0.4	5
384	Temporal trend, geographic distribution, and publication quality in asbestos research. <i>Environmental Science and Pollution Research</i> , 2015, 22, 6957-6967.	2.7	32
385	The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. <i>BMC Cancer</i> , 2015, 15, 374.	1.1	24
386	Genetic analysis of circulating tumor cells in pancreatic cancer patients: A pilot study. <i>Genomics</i> , 2015, 106, 7-14.	1.3	16
387	Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2015, 94, 99-108.	1.1	26
388	LIM-domain protein AJLUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade. <i>Oncogene</i> , 2015, 34, 73-83.	2.6	57
389	Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor. <i>Journal of Thoracic Disease</i> , 2016, 8, E379-E384.	0.6	13
390	Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor. <i>Case Reports in Pulmonology</i> , 2016, 2016, 1-5.	0.2	0
391	Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 279-288.	1.2	37

#	ARTICLE	IF	CITATIONS
393	SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2016, 49, 2411-2420.	1.4	9
394	Manumycin A induces apoptosis in malignant pleural mesothelioma through regulation of Sp1 and activation of the mitochondria-related apoptotic pathway. <i>Oncology Reports</i> , 2016, 36, 117-124.	1.2	8
395	Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma. <i>BMC Cancer</i> , 2016, 16, 455.	1.1	1
397	Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 29-36.	1.2	23
398	MnTE-2-PyP modulates thiol oxidation in a hydrogen peroxide-mediated manner in a human prostate cancer cell. <i>Free Radical Biology and Medicine</i> , 2016, 101, 32-43.	1.3	31
399	Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology. <i>Pediatric Dermatology</i> , 2016, 33, 18-27.	0.5	7
400	Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 94-107.	0.5	9
401	The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1615-1626.	0.5	74
402	Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells. <i>Cancer Gene Therapy</i> , 2016, 23, 425-432.	2.2	4
403	Overview of Infections in the Immunocompromised Host. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	79
404	Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2016, 49, 448-456.	1.4	31
405	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. <i>Tumori</i> , 2016, 102, 18-30.	0.6	8
406	Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth <i>In Vivo</i> by Affecting Stroma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1095-1105.	1.9	24
407	An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol. <i>SpringerPlus</i> , 2016, 5, 195.	1.2	8
408	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
409	Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. <i>Cancer Research</i> , 2016, 76, 319-328.	0.4	73
410	Asbestos and Mesothelioma. <i>Current Cancer Research</i> , 2017, , .	0.2	5
412	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2



#	ARTICLE	IF	CITATIONS
413	Resveratrol Improves Cell Cycle Arrest in Chronic Prostatitis Rats, by C-kit/SCF Suppression. DNA and Cell Biology, 2017, 36, 709-714.	0.9	3
414	Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematological Oncology, 2017, 35, 679-684.	0.8	32
415	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 2017, 34, 2232-2273.	1.3	407
416	Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. International Journal of Hematology, 2017, 106, 612-621.	0.7	14
417	Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies. Best Practice and Research in Clinical Haematology, 2017, 30, 184-192.	0.7	15
418	Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2017, 19, 65-71.	1.2	11
419	The Pharmacogenomic Association of Fcγ3 Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 169-175.	2.9	21
420	MicroRNA as Biomarkers of Malignant Mesothelioma. , 2017, , 203-221.		0
421	Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth. Frontiers in Immunology, 2017, 8, 1559.	2.2	44
422	Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review. Molecular and Clinical Oncology, 2017, 8, 34-37.	0.4	1
423	MR Imaging of Pleural Neoplasms. Topics in Magnetic Resonance Imaging, 2018, 27, 73-82.	0.7	11
424	Asbestos-Related Disease. Journal of Radiology Nursing, 2018, 37, 21-26.	0.2	8
425	Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> . Clinical Cancer Research, 2018, 24, 3729-3740.	3.2	24
426	Pathology of Malignant Mesothelioma. , 0, , 115-175.		0
427	4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. Investigational New Drugs, 2018, 36, 217-229.	1.2	9
428	Particle Toxicities. , 2018, , 263-301.		2
429	Malignant Mesothelioma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	1
430	Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer, 2018, 18, 1188.	1.1	26



#	ARTICLE	IF	CITATIONS
431	5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 27.	0.6	7
432	Mesothelioma in Sweden: Dose-Response Analysis for Exposure to 29 Potential Occupational Carcinogenic Agents. <i>Safety and Health at Work</i> , 2018, 9, 290-295.	0.3	3
433	New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2018, 8, 91.	1.3	46
434	Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin. <i>Frontiers in Immunology</i> , 2018, 9, 1189.	2.2	27
435	Prostate Carcinoma and Pleural Mesothelioma: An Extremely Rare Co-occurrence. <i>Cureus</i> , 2019, 11, e4655.	0.2	0
436	Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 806-811.	0.2	2
437	Malignant Mesothelioma: Has Anything Changed?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 347-360.	0.8	23
438	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4634-4643.	3.2	49
439	<p></p>Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobe on malignant lymphoma cells with CD20 overexpression</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 921-936.	3.3	22
440	<p></p>Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 773-785.	3.3	16
441	Infusion-related reactions to rituximab: frequency, mechanisms and predictors. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 383-389.	1.3	52
442	Multicenter analysis of the efficacy and safety of a non-steroid-resistant immunosuppressive therapy with rituximab in children with steroid-resistant nephrotic syndrome. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 313-321.	0.9	11
443	The Investigation of Lipoygenases as Therapeutic Targets in Malignant Pleural Mesothelioma. <i>Pathology and Oncology Research</i> , 2020, 26, 985-995.	0.9	0
444	Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. <i>Autoimmunity Reviews</i> , 2020, 19, 102466.	2.5	53
445	Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. <i>Cancers</i> , 2020, 12, 3553.	1.7	22
446	Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas. <i>Pathobiology</i> , 2020, 87, 208-216.	1.9	12
447	Hypoxia Inducible Factor-1 $\alpha$ Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells. <i>Anticancer Research</i> , 2020, 40, 1867-1874.	0.5	4
448	Rewiring carbohydrate catabolism differentially affects survival of pancreatic cancer cell lines with diverse metabolic profiles. <i>Oncotarget</i> , 2017, 8, 41265-41281.	0.8	16

#	ARTICLE	IF	CITATIONS
449	Red oil A5 inhibits proliferation and induces apoptosis in pancreatic cancer cells. World Journal of Gastroenterology, 2004, 10, 105.	1.4	8
450	Progress by Collaboration: ESPAC Studies. , 2004, , 57-69.		0
451	Appendix 2: Further Reading. , 0, , 442-449.		0